


AU 99 / 968



PCT/AU99/00968



EJU

09/807877

Patent Office  
Canberra

I, KAY WARD, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. PP 6976 for a patent by ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH filed on 06 November 1998.

WITNESS my hand this  
Sixteenth day of December 1999

KAY WARD  
TEAM LEADER EXAMINATION  
SUPPORT AND SALES



**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



AUSTRALIA  
Patents Act 1990

**PROVISIONAL SPECIFICATION**

**Applicant(s):** ST. VINCENT'S INSTITUTE OF MEDICAL RESEARCH

**Invention Title:** REGULATION OF ENZYME ACTIVITY

The invention is described in the following statement:

## REGULATION OF ENZYME ACTIVITY

This invention relates to the regulation of the activity of the enzyme nitric oxide synthase, and in particular regulation of activity of endothelial nitric oxide synthase. We have found that the activity of endothelial nitric oxide synthase is regulated by its phosphorylation by several protein kinases including protein kinase C and the AMP-activated protein kinase.

10

### BACKGROUND OF THE INVENTION

Nitric oxide (NO) has recently been recognised as an important mediator of a very wide variety of cellular functions, and is present in most if not all mammalian cells. It is implicated in a range of disorders, hypertension, hypocholesterolaemia, diabetes, heart failure, aging, inflammation, and the effects of cigarette smoking, and is especially important in vascular biology. NO is synthesised from the amino acid L-arginine by the enzyme nitric oxide synthase (NOS). Three isoforms of NOS have been identified: neuronal NOS (nNOS), which is found in neuronal tissues and skeletal muscle; inducible NOS (iNOS), found in a very wide variety of mammalian tissues including activated macrophages, cardiac myocytes, glial cells and vascular smooth muscle cells; and endothelial NOS (eNOS), found in vascular endothelium, cardiac myocytes and blood platelets.

These three isoforms have an amino acid sequence identity of approximately 55%, with strong sequence conservation in regions involved in catalysis. For all three isoforms, the mechanism of NO synthesis involves binding of the ubiquitous calcium regulatory protein calmodulin (CaM) to the enzyme. However, the conditions under which CaM is bound appear to be different for iNOS, at least insofar as calcium concentration is concerned. These three NOS enzymes have been intensively studied, and the field has been recently reviewed; see for example

Michel and Feron (1997); Harrison (1997); and Mayer and Hellens (1997). Although it was known from earlier studies that eNOS could be multiply phosphorylated, the mechanism of these phosphorylation events, including the enzyme  
5 responsible for phosphorylation, and the role of phosphorylation in modulation of eNOS function was not known.

AMP-activated protein kinase (AMPK) is a metabolic stress-sensing protein kinase that is known to  
10 play an important role in the regulation of acetyl-CoA carboxylase, leading to the acceleration of fatty acid oxidation during vigorous exercise or ischaemia. AMPK is well known as a regulator of lipid metabolism, and in particular is known to have a role in cholesterol  
15 synthesis, reviewed in Hardie and Carling (1997).

AMPK has mainly been studied in the liver, heart and skeletal muscle. AMPK has been purified, and the genes encoding the enzyme subunits have been cloned (see International Patent Applications No. PCT/GB94/01093 and  
20 No. PCT/US97/00270).

The mammalian AMPK (Mitchelhill et al, 1994) is related to the *Saccharomyces cerevisiae* SNF1 protein kinase, which is required for the expression of glucose-repressed genes during nutritional stress, permitting  
25 growth on alternative carbon sources (Celenza and Carlson, 1986); both the mammalian and yeast kinases are activated by upstream kinases (Hardie and Carling, 1997). The AMPK is involved in metabolic stress responses through phosphorylation and concomitant inhibition of acetyl-CoA  
30 carboxylase and HMG-CoA reductase (Hardie and Carling, 1997). Multiple AMPK isoforms occur, comprising heterotrimers of  $\alpha 1$  or  $\alpha 2$  catalytic subunits (63 kDa) (Stapleton et al, 1996; Stapleton et al, 1997a), together with  $\beta$  (40 kDa) and  $\gamma$  (38 kDa) non-catalytic subunits  
35 (Mitchelhill et al, 1994; Carling et al, 1994; Stapleton et al, 1994), related to the yeast sip1p and snf4p respectively.

The gene encoding the  $\alpha 2$  sub-unit of AMPK has been localised to chromosome 1 Beri et al (1994), while the gene for the  $\alpha 1$  sub-unit is on chromosome 5, and those for the  $\beta 1$  and  $\gamma 1$  sub-units are both on chromosome 12; the gene  
5 encoding the  $\gamma 2$  sub-unit is localised on chromosome 7 (Stapleton et al, 1997).

One of the genes encoding eNOS is on chromosome 7, close to the gene for the  $\gamma 2$  sub-unit of AMPK. Another gene encoding nNOS is found on  
10 chromosome 12. (The human gene map SEE <http://www.ncbi.nlm.nih.gov/cgi-bin/SCIENCE96/tsrch?QTEXT=nitric+oxide+synthase>)

Recent work has shown that the AMPK in cardiac and skeletal muscle is activated by vigorous exercise or  
15 ischaemic stress (Winder and Hardie, 1996; Vavvas, et al, 1997; Kudo et al, 1995). This led us to investigate the localization of the AMPK isoforms in these tissues. The AMPK- $\alpha 2$  isoform is present in capillary endothelial cells in cardiac and skeletal muscle and the AMPK- $\alpha 1$  isoform  
20 occurs in cardiac myocytes and vessels (results not shown). The presence of AMPK in endothelial cells prompted us to test bacterially expressed eNOS as a substrate, and we found that it is readily phosphorylated by either AMPK- $\alpha 1$  or AMPK- $\alpha 2$ .

25 We have now surprisingly found that the AMP-activated protein kinase phosphorylates and regulates endothelial NO synthase. We find that the AMPK phosphorylates eNOS at two sites. In the presence of calcium and calmodulin, Ser-1177 is phosphorylated in the  
30 COOH-terminal tail of the enzyme, causing activation of eNOS by shifting the calmodulin-dose dependence. In the absence of added calcium and calmodium, phosphorylation also occurs at Thr-495 in the eNOS calmodulin-binding sequence, and inhibits the enzyme. Ischaemia of the heart  
35 causes activation of the AMPK and of eNOS, mimicking the effects of phosphorylation at Ser-1177. Phosphopeptide specific antibodies to phosphorylated Ser-1177 were used to

confirm that this site was phosphorylated during ischaemia. Phosphorylation of eNOS at Thr-495 by protein kinase C occurs in endothelial cells that have been serum starved and incubated in calcium free media in the presence of  
5 phorbol ester. Our results are of special interest because they define a link between metabolic stress that reduces ATP and increases AMP and signalling through eNOS to control nutrient supply via arterial vasodilation, as well as reducing myocardial contraction, thus coupling the  
10 metabolic status of endothelial cells and myocytes with the vascular supply and mechanical activity. Our results provide a new insight into the post-translational regulation of eNOS that is of particular significance for the cardiovascular and skeletal muscle field.

15

#### SUMMARY OF THE INVENTION

According to a first aspect, the invention provides a method of identifying modulators of AMPK-mediated activation of eNOS, comprising the step of testing  
20 putative modulators for their ability to increase or decrease phosphorylation of eNOS depending on the calmodulin and calcium ion concentrations.

Preferably the specific phosphorylation of Ser-1177 is assessed in the presence of calcium and  
25 calmodulin.

In an alternative aspect, the invention provides a method of identifying modulators of AMPK-mediated inhibition of eNOS, comprising the step of testing a  
putative modulator for its ability to decrease or increase  
30 AMPK-mediated phosphorylation of eNOS in the presence of limiting calcium ions. Preferably specific phosphorylation of threonine 495 is assessed.

Compounds able to increase phosphorylation of Ser-1177 or decrease phosphorylation of Thr-495 are  
35 referred to herein as activators, and compounds able to decrease phosphorylation of Ser-1177 or increase phosphorylation of Thr-495 are referred to as inhibitors.

In both aspects of the invention, one or more of the following activities may optionally be additionally assessed for each putative activator or inhibitor identified by the method of the invention:

- 5           1. Effect on smooth muscle contraction;
2. Effect on inotropic activity of the heart;
3. Effect on chronotropic activity of the hear.

It is expected that because the phosphorylation site equivalent to Thr-495 in the eNOS calmodulin-binding  
10 site is absent from the neuronal form of NOS, inhibitors and activators identified by the method of the invention will have at least some degree of tissue specificity.

Compounds that activate the AMP-activated protein kinase are expected to be useful in ischaemic heart disease  
15 both by promoting glucose and fatty acids metabolism as well as by increasing NOS activity to improve nutrient and oxygen supply to the myocytes and reduce mechanical activity. These compounds would also have utility in pulmonary hypertension and in obstructive airways disease.

20           For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.

## 25   BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows immunofluorescence localization of AMPK- $\alpha$ 2 in the heart and in the tibialis anterior muscle.

Panel A shows a negative control section of rat heart stained with control rabbit IgG and control mouse  
30 IgG, together with anti-rabbit-FITC and anti-mouse-Texas Red.

Panel B shows a section of rat heart stained with affinity-purified rabbit polyclonal antibody against AMPK- $\alpha$ 2 (490-514) and anti-rabbit-FITC.

35           Panel C shows the same section as Panel B, stained with a monoclonal antibody against rat endothelium recA-1 and anti-mouse-Texas Red.



Panel D shows the overlay of Panels B and C. Colocalization can be seen by the coincidence of staining. The arrows highlight specific endothelial cells that are stained by both antibodies.

5 Panel E shows a negative control section of rat tibialis anterior muscle stained with control rabbit IgG and control mouse IgG, together with anti-rabbit-FITC and anti-mouse-Texas Red.

10 Panel F shows a section stained with affinity-purified rabbit polyclonal antibody against AMPK- $\alpha$ 2 (490-514) and anti-rabbit-FITC.

Panel G shows the same section as in Panel B, stained with a monoclonal antibody against rat endothelium recA-1 and anti-mouse-Texas Red.

15 Panel H shows the overlay of Panels E and F. Colocalization can be seen by the coincidence of staining.

Figure 2 illustrates phosphorylation of recombinant eNOS by AMPK.

20 Top panel: eNOS was incubated with rat liver AMPK- $\alpha$ 1 and [ $\gamma$ - $^{32}$ P] ATP.

Lane 1: Coomassie-stained SDS-PAGE;

Lane 2: Autoradiograph.

Lower panel:  $^{32}$ P-tryptic phosphopeptide map of eNOS.

25 Figure 3 shows the effect of phosphorylation of eNOS by the AMPK with or without added  $\text{Ca}^{2+}$ -CaM. Rat heart eNOS purified by 2',5'-ADP-Sepharose affinity chromatography was phosphorylated by AMPK in the presence of 0.8  $\mu\text{M}$  CaM/3.2  $\mu\text{M}$   $\text{Ca}^{2+}$  (closed circles), in the absence of  $\text{Ca}^{2+}$ -CaM (closed triangles) and without AMPK (open squares). After phosphorylation, the samples were diluted, eNOS activity was measured. The lower panels show phosphopeptide maps for rat heart eNOS phosphorylated in the presence and absence of added  $\text{Ca}^{2+}$ -CaM.

35 Figure 4 shows the effect of ischaemia on the activities of AMPK- $\alpha$ 1, AMPK- $\alpha$ 2 and eNOS.

Panel A shows the results of immunoprecipitation using antibody specific for AMPK- $\alpha$ 1 and AMPK- $\alpha$ 2, assayed using the SAMS peptide substrate. Results shown are mean  $\pm$  SEM for n=5.

5 Panel B shows eNOS activity measured at 500 nM CaM.

Panel C shows eNOS activities with full CaM-dose responses for a representative experiment. Ischaemia time points: 0 min (open squares), 1 min (closed diamonds), 10 min (closed circles) and 20 min (open triangles). The results of 4 replicates were the same, except that in one case the 20 min ischaemia eNOS CaM-dependence remained the same as for 10 min.

Figure 5 shows a comparison of NOS phosphorylation site sequences for eNOS, nNOS and iNOS, in a schematic model of NOS. Sequences from the CaM-binding region (around the Thr-495 phosphorylation site in eNOS) and for the COOH-terminal tail (around the Ser-1177 phosphorylation site in eNOS) are shown.

20

#### DETAILED DESCRIPTION OF THE INVENTION

The invention will now be described in detail by way of reference only to the following non-limiting examples and to the figures.

25 We have surprisingly found that in the presence of Ca<sup>2+</sup>-calmodulin (CaM) eNOS is phosphorylated by AMPK at Ser-1177, resulting in activation, whereas phosphorylation of eNOS in the absence of Ca<sup>2+</sup> occurs predominantly at Thr-495, a site in the CaM-binding sequence, resulting in inhibition. It had previously been considered that phosphorylation was solely inhibitory. We have also found that ischaemia of the heart leads to rapid activation of both isoforms of the metabolic stress-sensing enzyme AMPK and eNOS. These data suggest that the AMPK may operate an  
30 "inside-out" signalling pathway that leads to arterial vasodilation and reduced myocardial contraction, so  
35

coupling the metabolic status of endothelial cells and myocytes with the vascular supply and mechanical activity.

Example 1                      Immunofluorescence Localisation of AMPK- $\alpha$ 2  
5                                      in Heart and Skeletal Muscle

Confocal immunofluorescence microscopy using affinity-purified rabbit polyclonal antibody directed against AMPK- $\alpha$ 2 (antibody 490-414); (Stapleton *et al*, 1996) and staining with fluorescence-labelled anti-rabbit  
10 antibody showed that the  $\alpha$ 2 isoform is found predominantly in capillary endothelial cells in both cardiac muscle and skeletal muscle, while cardiac myocytes and blood vessels showed intense but diffuse staining for the  $\alpha$ 1 isoform of  
15 AMPK. In skeletal muscle, the  $\alpha$ 2 isoform was found in endothelial cells of capillaries, and in fast-twitch muscle fibres, whereas the  $\alpha$ 1 isoform was found in Type I aerobic fibres. Localisation of AMPK- $\alpha$ 2 in capillary endothelial cells in both cardiac and skeletal muscle is illustrated in  
20 Figure 1.

Example 2                      AMPK Phosphorylates Recombinant eNOS

Bacterially expressed eNOS, coexpressed with CaM by the method of Rodriguez-Crespo *et al* (1996), was phosphorylated by either AMPK- $\alpha$ 1, as shown in Figure 2 top  
25 panel, or AMPK- $\alpha$ 2. Recombinant eNOS phosphorylation by immunoprecipitated AMPK- $\alpha$ 2 (Stapleton *et al*, 1996) was detected. Since we have been unable to purify high specific activity AMPK- $\alpha$ 2, no further characterization of eNOS regulation or the sites of phosphorylation by the  $\alpha$ 2  
30 isoform was undertaken. Analysis of the phosphorylation sites in eNOS following tryptic digestion revealed four phosphopeptides generated from three separate sites (Figure 2 bottom panel, A, A', B, C). Identification of phosphorylation sites by mass spectrometry and Edman  
35 sequencing, using the method described by Mitchelhill *et al*, 1997a, revealed that Ser-1177 was the most prominent phosphorylation site, as shown in Figure 2 bottom panel, A,

A', and that its phosphorylation was dependent on the presence of  $\text{Ca}^{2+}$ -CaM.

Phosphopeptide isolation from in-gel tryptic digests was carried out as described by Mitchelhill *et al*,  
5 1997a. Greater than 98% of the radioactivity was recovered from the gel. Peptides isolated and characterized by mass spectrometry and Edman sequencing were set out in Table 1.

Table 1  
Phosphopeptides Isolated from In-Gel tryptic Digests

	Observed Mass	Phosphopeptide	Sequence	Calculated Mass
5	1440.0	B	KKTFKEVANAVK	1361.1 (*1441.7)
	1174.1	A	TQXFSLQER	1094.5 (*1174.5)
	1445.6	A'	IRTQXFSLQER	1363.7 (*1443.7)
	1176.7	C	pCLGSLVFPR	1095.6 (*1175.6)

where: "pc" denotes pyridylethyl cysteine.

\* denotes calculated mass of mono-phosphorylated peptide.

The location of the phosphorylation site in peptide A, TQXFSLQER, was identified by  $^{32}\text{P}$ -phosphate release sequencing (Mitchell et al, 1997a). eNOS phosphorylated by the AMPK- $\alpha$ 1 was no longer recognized by the antibody to the eNOS COOH-terminal tail; nor was it elute from the ADP-Sepharose affinity column by 100 mM NADPH. These properties prevented the direct confirmation of Ser-1177 phosphorylation *in situ*. This is illustrated in Venema et al, 1996.

A second site, Thr-495, was phosphorylated in the absence of  $\text{Ca}^{2+}$ -CaM or when EGTA was present. This is illustrated in Figure 2 bottom panel, B. This residue is located in the CaM-binding sequence,

TRKKT<sup>495</sup>FKEVANAVKISASLM,

between the oxidase and reductase domains of eNOS (Venema et al, 1996). Ser-101 in the N-terminal region of eNOS was identified as a minor site of phosphorylation (Figure 2 bottom panel, C).

Synthetic peptides containing Thr-495 or Ser-1177 were readily phosphorylated by AMPK, with similar kinetic values to the SAMS peptide substrate. The peptide containing Thr-495, GTGITRKKT<sup>495</sup>FKEVANAVK, was phosphorylated with a  $K_m$  of  $39 \pm 10 \mu\text{M}$  and a  $V_{max}$  of  $6.7 \pm 0.6 \mu\text{mol/min/mg}$ , whereas the peptide containing Ser-1177, RIRTQSFSLQERQLRG was phosphorylated with a  $K_m$  of  $54 \pm 6 \mu\text{M}$  and a  $V_{max}$  of  $5.8 \pm 0.3 \mu\text{mol/min/mg}$ . These are comparable to results obtained using the well-characterized SAMS peptide substrate, which has a  $K_m$   $33 \pm 3 \mu\text{M}$  and a  $V_{max}$  of  $8.1 \pm 1.5 \mu\text{mol/min/mg}$  (Mitchell et al, 1996). The *in vitro* phosphorylation of the peptides confirms the identification sites of phosphorylation.

### Example 3                      Effect of $\text{Ca}^{2+}$ -CaM on Phosphorylation of eNOS by AMPK

The eNOS activity was determined by measuring L-[ $^3\text{H}$ ]-citrulline production, using the method of Balligand et al, 1995. The recombinant eNOS was coexpressed with

CaM, as described by Rodriguez-Crespo and Ortiz de Montellano, 1996. Partially-purified rat heart eNOS contained some  $\text{Ca}^{2+}$ -CaM. In the absence of added EGTA, CaM dependence was observed at 0-100 nM added CaM. In order to  
5 investigate the changes in NOS activity with phosphorylation in the absence and presence of  $\text{Ca}^{2+}$ -CaM, EGTA buffering was used to achieve CaM dose response curves in the range 0-1  $\mu\text{M}$ . Routinely, 7-15  $\mu\text{M}$  EGTA was added to make eNOS activity dependent upon added CaM. Where  
10  $\text{Ca}^{2+}$ -CaM was used in the phosphorylation reaction prior to eNOS assay, the samples were either diluted so that the extra  $\text{Ca}^{2+}$ -CaM was negligible, or the indicated concentrations represent total final concentrations of added  $\text{Ca}^{2+}$ -CaM.

15 Cardiac eNOS was partially purified as follows:  
20 rat hearts were homogenized in 80 ml of ice-cold buffer A [50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 50 mM NaF, 5 mM Na Pyrophosphate, 10  $\mu\text{g}/\text{ml}$  Trypsin inhibitor, 2  $\mu\text{g}/\text{ml}$  Aprotinin,  
20 1 mM Benzamidine, 1 mM PMSF, 10% Glycerol, 1% Triton-X-100]. The homogenate was put on ice for 30 min and centrifuged at 16,000 x g for 30 min. The supernatant was incubated with 2 ml of 2',5'-ADP-Sepharose (Bredt and Snyder, 1990). After one hour incubation, the suspension  
25 was poured into a fritted column, which was washed with 20 ml of buffer A and 20 ml of buffer A with 0.5 M NaCl, and then with 20 ml of buffer B [50 mM Tris-HCl, pH 7.5, 1 mM DTT, 10% Glycerol, 0.1% Triton-X-100]. eNOS was eluted with buffer B containing 2 mM NADPH, then subjected  
30 to centrifugal filtration (ULTRAFREE-MC MILLIPORE) to remove NADPH. Immunoblotting was used for selective detection of eNOS rather than nNOS.

Phosphorylation of eNOS by AMPK in the presence of  $\text{Ca}^{2+}$ -CaM resulted in activation, but CaM-dependence was  
35 retained, as shown in Figure 3 top panel. Activation shifted the dose response curve for CaM to the left. Phosphopeptide mapping revealed that activation of eNOS was

correlated with phosphorylation of Ser-1177 but not of Thr-495, as shown in Figure 3 lower panel. Phosphorylation without added  $\text{Ca}^{2+}$ -CaM enhanced Thr-495 phosphorylation, suppressed Ser-1177 phosphorylation, and inhibited eNOS activity (Figure 3 top panel). The inhibition of eNOS activity by Thr-495 phosphorylation is consistent with earlier reports that phosphorylation of synthetic peptides corresponding to this region by protein kinase C inhibits CaM-binding (Matsubara et al, 1996). Similar results have been reported for nNOS (Loche et al, 1997).

Example 4                      Effect of Ischaemia on Activities of  
AMPK- $\alpha$ 1, AMPK- $\alpha$ 2 and eNOS

Langendorf preparations of isolated perfused rat heart were subjected to ischaemia according to the method of Kudo et al (1995). AMPK- $\alpha$ 1 and AMPK- $\alpha$ 2 isoforms were immunoprecipitated using  $\alpha$ 2 (490-516) or  $\alpha$ 1 (231-251) antibodies, and assayed using the SAMS peptide substrate (Michell et al, 1996; Hardie and Carling, 1997). eNOS activity was measured as described in Example 3. The results are shown in Figure 4. Both  $\alpha$ 1 and  $\alpha$ 2 isoforms, are activated, as shown in Figure 4A, indicating that AMPK is activated in both capillary endothelial cells, which have predominantly the  $\alpha$ 2 isoform, and in cardiac myocytes, which have predominantly the  $\alpha$ 1 isoform. AMPK activation during ischaemia is also accompanied by eNOS activation and changes in the CaM dependence, as shown in Figures 4B and 4C, mimicking the effect of eNOS phosphorylation by AMPK *in vitro*, as shown in Figure 3.

Polyclonal antibodies were raised against synthetic phosphopeptides based on the eNOS sequence: RIRTQSpFSLQER and GITRKKTpFKEVANCV. Rabbits were immunized with phosphopeptides coupled to keyhole limpet haemocyanin and then emulsified in Freund's complete adjuvant, using conventional methods. The antibodies were purified using the corresponding phosphopeptide affinity columns after thorough preclearing with dephosphopeptide affinity



columns. The specificity of the purified antibodies was confirmed using both EIA and immunoblotting, confirming that they did not recognize recombinant dephospho-eNOS.

Using the anti-phosphopeptide antibodies to Ser-1177 and Thr-495 phosphorylation sites we observed that phosphorylation of Ser-1177 was increased approximately 3-fold with ischaemia, but that there was no detectable change in the Thr-495 phosphorylation under these conditions. Heart muscle contains eNOS in both capillary endothelial cells and cardiac myocytes (Balligand et al, 1995), with low levels of the nNOS  $\mu$  isoform (Silvagno et al, 1996).

The sequences of the three types of NOS are compared in Figure 5, which shows the CaM-binding region and the C-terminal tail. In nNOS Ser-1417 corresponds to eNOS Ser-1177, whereas iNOS is truncated, and has a Glu in this region. Both iNOS and nNOS lack a phosphorylatable residue equivalent to Thr-495.

#### 20 Example 5      Effect of Stimulation of Protein Kinase C on eNOS Phosphorylation

Bovine aortic endothelial cells cultured in 0.1% foetal calf serum for 20 hours (serum starved) were subjected to treatment with the protein kinase C activator 0.1  $\mu$ M phorbol-12-myristate-13-acetate (PMA) for 30 min. PMA treatment increased the phosphorylation of eNOS at Thr-495 and decreased the phosphorylation at Ser-1177, as measured using anti-phosphopeptide specific antibodies. The antibodies used were the same as those described in Example 4. The response was most marked when the cells were incubated in medium lacking added calcium.

#### DISCUSSION

Activation of eNOS by phosphorylation of its COOH-terminal tail gives new insight into eNOS autoinhibition. The increased activity and shift in the CaM-dose dependence with phosphorylation at Ser-1177

suggest that in eNOS, and perhaps nNOS, the COOH-terminal tails act as partial autoregulatory sequences analogous to those in the CaM-dependent protein kinases (Kemp and Pearson, 1991; Kobe et al, 1996).

5           The COOH-terminal tail of eNOS is only fully accessible to the AMPK when  $\text{Ca}^{2+}$ -CaM is bound, consistent with this region being buried in the absence of Cam. As can be seen from Figure 5, there is a high level of similarity between eNOS and nNOS in their COOH-terminal  
10 tails, whereas iNOS is distinct. It is known that the iNOS CaM-binding, which is characterised by a low  $\text{Ca}^{2+}$ -dependence, requires both the canonical CaM-binding sequence and distal residues in the COOH-terminus that cannot be satisfied by nNOS chimeras (Ruan et al, 1996).  
15 Without wishing to be bound by any proposed mechanism, we believe that eNOS and nNOS are autoinhibited by their COOH-terminal tails, requiring a two-stage activation process for full activity with both CaM-binding and phosphorylation in the tail, whereas iNOS requires only CaM  
20 binding. Recently, Salerno et al (1997) proposed that an insert sequence in the FMN-binding domain may also be important in autoregulation.

Previous studies have shown that eNOS may be phosphorylated both *in vitro* and *in vivo*, but the precise  
25 sites of phosphorylation and the function of the phosphorylation events have not hitherto been fully characterized (reviewed in Michel and Feron, 1997). eNOS is the first example of an enzyme activated by AMPK to be identified, and is also unusual because phosphorylation can  
30 lead to either activation or inhibition, depending on the availability of  $\text{Ca}^{2+}$ -CaM. Other enzymes, notably the cyclin-dependent protein kinases, are activated or inhibited by phosphorylation, but this is catalysed by different protein kinases. Protein kinase C phosphorylates  
35 Thr-495 in eNOS, demonstrating intersecting regulatory pathways acting on eNOS by phosphorylation of Thr-495 or Ser-1177. It is also possible that persistent activation

of protein kinase C could block eNOS activation by AMPK during metabolic stress.

5 The regulation of eNOS by AMPK extends the conceptual relationship between the yeast snflp kinase and the AMPK. Whereas the snflp kinase modulates the supply of nutrients from the environment by secreting invertase, the mammalian AMPK has been used to integrate metabolic stress signalling with the control of the circulatory system, so that intracellular metabolic stress signals within  
10 endothelial cells and myocytes can elicit improved nutrient supply and suppress mechanical activity of the muscle.

15 It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this  
20 specification.

Reference cited herein are listed on the following pages, and are incorporated herein by this reference.

REFERENCES

- Balligand, J.L., Kobzik, L., Han, X., Kaye, D.M.,  
Belhassen, L., O'Hara, D.S., Kelly, R.A., Smith, T.W. and  
5 Michel, T.  
J. Biol. Chem., 1995 270 14582-14586
- Beri, R.K. and Marley, A.E.  
See, C.G., Sopwith, W.F., Aguan, K., Carling, D.,  
10 Scott, J., and Carey, F.  
Febs Lett, 1994 356 117-121
- Bredt, D.S. and Snyder, S.H.  
Proc. Natl. Acad. Sci. USA, 1990 87 682-685  
15
- Carling, D., Aguan, K., Woods, A., Verhoeven, A.J.M.,  
Beri, R., Brennan, C.H., Sidebottom, C., Davidson, M.D. and  
Scott, J.  
J. Biol. Chem., 1994 269 11442-11448  
20
- Celenza, J.L. and Carlson, M.  
Science, 1986 233 1175-1180
- Hardie, D.G. and Carling, D.  
25 Eur J Biochem., 1997 246 259-273
- Kemp, B.E. and Pearson, R.B.  
Biochim. Biophys. Acta, 1991 1094 67-76
- 30 Kobe, B., Heierhorst, J., Feil, S.C., Parker, M.W.,  
Benian, G.M., Weiss, K.R. and Kemp, B.E.  
Embo. J., 1996 15 6810-6821
- Kudo, N., Barr, A.J., Barr, R.L., Desai, S.,  
35 Lopaschuk, G.D.  
J. Biol. Chem., 1995 270 17513-17520

Matsubara, M., Titani, K. and Taniguchi, H.  
Biochemistry, 1996 35 14651-14658

Michel, T. and Feron, O.

- 5 J. Clin. Invest., 1997 100 2146-2152

Michell, B.J., Stapleton, D., Mitchelhill, K.I.,  
House, C.M., Katsis, F., Witters, L.A. and Kemp, B.A.  
J. Biol. Chem., 1996 271 28445-28450

10

Mitchelhill, K.I., Michell, B.J., House, C.,  
Stapleton, D., Dyck, J., Gamble, J., Ullrich, C.,  
Witters, L.A., and Kemp, B.E.  
J. Biol. Chem., 1997 272 24475-24479

15

Mitchelhill, K.I., Stapleton, D., Gao, G., House, C.,  
Michell, B., Katsis, F., Witters, L.A. and Kemp, B.E.  
J. Biol. Chem., 1994 269 2361-2364

- 20 Rodriguez-Crespo, I., Ortiz de Montellano, P.R.  
Arch. Biochem. Biophys., 1996 336 151-156

Ruan, J., Xie, Q., Hutchinson, N., Cho, H., Wolfe, G.C. and  
Nathan, C.

- 25 J. Biol. Chem., 1996 271 22679-22686

Salerno, J.C., Harris, D.E., Irizarry, K., Patel, B.,  
Morales, A.J., Smith, S., Martasek, P., Roman, L.J.,  
Masters, B., Jones, C.L., Weissman, B.A., Lane, P. et al.

- 30 J. Biol. Chem., 1997 272 29769-29777

Silvagno, F., Xia, H. and Bredt, D.S.  
J. Biol. Chem., 1996 271 11204-11208

Stapleton, D., Guang, G., Michell, B.J., Widmer, J.,  
Mitchelhill, K.I., Teh, T., House, C.M., Witters, L.A. and  
Kemp, B.E.

J. Biol. Chem., 1994 269 29343-29346

5

Stapleton, D., Mitchelhill, K.I., Gao, G., Widmer, J.,  
Michell, B.J., Teh, T., House, C.M., Fernandez, C.S., Cox,  
T., Witters, L.A. and Kemp, B.E.

J. Biol. Chem., 1996 271 611-614

10

Stapleton, D.A., Woollatt, E., Mitchelhill, K.I.,  
Nicholl, J.K., Fernandez, C.S., Michell, B.J.,  
Witters, L.A., Power, D.A., Sutherland, G.R. and Kemp, B.E.  
FEBS Lett., 1997 409 452-456

15

Stapleton, D., Woollatt, E., Mitchelhill, K.I.,  
Nicholl, J.K., Fernandez, C.S., Michell, B.J.,  
Witters, L.A., Power, D.A., Sutherland, G.R. and Kemp, B.E.  
Febs Lett, 1997 411 452-456

20

Vavvas, D., Apazidis, A., Saha, A.K., Gamble, J.,  
Patel, A., Kemp, B.E., Witters, L.A. and Ruderman, N.B.  
J. Biol. Chem., 1997 272 13255-13261

25 Venema, R.C., Sayegh, H.S., Kent, J.D., Harrison, D.J.  
J. Biol. Chem., 1996 271 6435-6440

Winder, W.W. and Hardie, D.G.

Am. J. Physiol., 1996 270 E299-E304

30

Zoche, M., Beyermann, M. and Koch, K.W.  
Biol. Chem., 1997 378 851-857

ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH




FIGURE 1






FIGURE 2





eNOS + AMPK  
+ Ca<sup>2+</sup>-CaM

eNOS + AMPK



FIGURE 3




FIGURE 4




FIGURE 5

THIS PAGE BLANK (USPTO)